RNXT
RenovoRx Roars into Commercial Phase with Strong First Year of RenovoCath Adoption
The year 2025 marked a significant milestone for RenovoRx, as it transitioned from a clinical development phase to commercialization with its patented TAMP therapy platform. Speaking at the company's Q4 2025 financial results conference call, CEO Shaun Bagai emphasized that this evolution reflects a deliberate and positive step